Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-01
2008-01-01
Ewoldt, G. R. (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S185100, C530S324000, C530S325000, C530S326000, C530S327000, C530S328000
Reexamination Certificate
active
07314856
ABSTRACT:
A method for promoting bone growth in a patient (e.g., a mammal such as a human) said method including the step of administering a therapeutically effective amount of adrenomedullin or an adrenomedullin agonist to said patient.
REFERENCES:
patent: 5478847 (1995-12-01), Draper
patent: 5922677 (1999-07-01), Reid
patent: 0 622 458 (1994-11-01), None
patent: WO97 07214 (1997-02-01), None
patent: WO97/38704 (1997-10-01), None
patent: WO99/16406 (1999-04-01), None
Hinson et al. “Adrenomedullin, a multifunctional regulatory peptide” Endocrine Reviews, 2000, 21:138-167.
Schmidt et al. “Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxins” Int. J. Cancer, 2002, 97:349-356.
Cheng et al., “Synthetic Human Adrenomedullin and ADM15-52 Have Potent Short-Lasting Vasodilator Activity In The Pulmonary Vascular Bed of the Cat”,Life Sciences, 55:PL251-PL256, 1994.
Cornish et al.,BBRC, 207(1):133-139, 1995.
DeWitt et al.,European J. Pharmacol., 257:303-306, 1996.
Eguchi et al., “Structure-Activity Relationship of Adrenomedullin, a Novel Vasodilatory Peptide, in Cultured Rat Vascular Smooth Muscle Cells”,Endrocrinology, 135:2454-2458, 1994.
Hao et al., “An Adrenomedullin (ADM) Fragment Retains the Systemic Vasodilator Activity of Human ADM”,Life Sciences, 54:PL265-PL270, 1994.
Ichiki et al., “Distribution and Characterization of Immunoreactive Adrenomedullin in Human Tissue and Plasma”,FEBS Letters, 338:6-10, 1994.
Ishiyama et al., “Hemodynamic Effects of a Novel Hypotensive Peptide, Human Adrenomedullin, In Rats”,European Journal of Pharmacology, 241:271-273, 1993.
Kanazawa et al., “Adrenomedullin, A Newly Discovered Hypotensive Peptide, Is a Potent Bronchodilator”, 205:251-254, 1994.
Kitamura et al., “Adrenomedullin: A Novel Hypotensive Peptide Isolated From Human Pheochromocytoma”,Biochemical&Biophysical Research Comm., 192:553-560, 1993.
Kitamura et al., “Cloning and Characterization of cDNA Encoding a Precursor for Human Adrenomedullin”,Biochemical&Biophysical Research Comm., 194:720-725, 1993.
Kitamura et al., “Complete Amino Acid Sequence of Porcine Adrenomedullin and Cloning of cDNA Encoding its Precursor”,FEBS Letters, 338:306-310, 1994.
Lin et al., “An Adrenomedullin Fragment Retains the Systemic Vasodepressor Activity of Rat Adrenomedullin”,European Journal of Pharmacology, 260:1-4, 1994.
Lippton et al., “Adrenomedullin Dilates the Pulmonary Vascular Bed In Vivo”,J. Appl. Physiol., 76:2154-2156, 1994.
Muff et al., “Calcitonin, Calcitonin Gene-related Peptide, Adrenomedullin and Amylin: Homologous Peptides, Separate Receptors and Overlapping Biological Actions”,European Journal of Endocrinology, 133:17-20, 1995.
Nuki et al., “Vasodilator Effect of Adrenomedullin and Calcitonin Gene-Related Peptide Receptors In Rat Mesenteric Vascular Beds”,Biochemical and Biophysical Research Comm., 196:245-251, 1993.
Owji et al., “An Abundant and Specific Binding Site for the Novel Vasodilator Adrenomedullin in the Rat”,Endocrinology, 136:2127-2134, 1995.
Perret et al., “The Effect of Adrenomedullin on the Isolated Heart”,Life Sciences, 53:PL377-379, 1993.
Sakata et al., “Molecular Cloning and Biological Activities of Rat Adrenomedullin, A Hypotensive Peptide”,Biochemical and Biophysical Research Comm., 195:921-927, 1993.
Santiago et al., “Comparison of Responses to Adrenomedullin and Adrenomedullin Analogs in the Mesenteric Vascular Bed of the Cat”,European Journal of Pharmacology, 272:115-118, 1995.
Santiago et al., “Synthetic Human Adrenomedullin and Adrenomedullin 15-52 Have Potent Short-Lived Vasodilator Activity in the Hindlimb Vascular Bed of the Cat”,Life Sciences, 55:PL85-PL90, 1994.
Zimmermann et al., “Adrenomedullin and Calcitonin Gene-Related Peptide Interact With the Same Receptor in Cultured Human Neuroblastoma SK-N-MC Cells”,Peptides, 16:421-424, 1995.
Cornish et al., “Adrenomedullin is a Potent Stimulator of Osteoblastic Activity In Vitro and In Vivo”, American Physiological Society, , (1997), 273, pp. E1113-E1120.
Wimalawansa et al., “Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily”, Critical Reviews in Neurobiology 11:167-239, 1997.
GenBank Accession Number AAW25159; Dec. 8, 1997.
Belloni et al., “Inhibitory Effect of Adrenomedullin (ADM) on the Aldosterone . . . ”, 1998, Life Sciences, vol. 63, No. 26;2313-2321.
Cornish et al., “Systemic administration of adrenomedullin (27-52) increases . . . ”, 2001, J. Endocrinology, vol. 170;251-257.
Cornish et al., “Skeletal Effects of Amylin . . . ”, 1999, Endocrinologist; 183-189.
Watanabe et al., “Vasopressor Activities of N-Terminal Fragments . . . ”, 1996, Biochem and Biophysical Research Commun., vol. 219;59-63.
Cooper Garth James Smith
Cornish Jillian
Reid Ian Reginald
Auckland UniServices Limited
Ewoldt G. R.
Fish & Richardson P.C.
Szperka Michael
LandOfFree
Adrenomedullin agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adrenomedullin agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adrenomedullin agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2758793